Regentis Biomaterials Set to Begin European Surgeon Training for GelrinC Cartilage Implant

Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026, a critical step in preparing for the commercial launch of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on training program, expected to start at Humanitas Research Hospital in Milan, Italy, will provide orthopedic surgeons with practical experience using the company's cell-free implant, with additional sessions planned across Europe.

The training initiative is part of Regentis' broader European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance, and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair. By expanding physician familiarity with the technology, Regentis aims to drive adoption as the product enters broader clinical use.

The move addresses a significant market opportunity. According to the company, approximately 470,000 cases of cartilage knee repair occur annually in the U.S. alone, where no off-the-shelf treatment is currently available. GelrinC, a cell-free, off-the-shelf hydrogel, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This unique mechanism could offer a viable solution for patients suffering from knee cartilage lesions, potentially reducing the need for more invasive procedures.

Regentis' focus on surgeon training underscores the importance of education in the adoption of new medical technologies. By establishing Centers of Excellence, the company hopes to create a network of skilled practitioners who can share best practices and clinical outcomes, thereby building confidence in GelrinC's efficacy and safety. The training program is expected to commence in Q3 2026, with details on additional locations to be announced.

For more information on the press release, visit https://ibn.fm/QOWWK. Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions, with an initial focus on orthopedic treatments. However, this article includes forward-looking statements that involve risks and uncertainties, as detailed in the company's filings with the SEC. Investors are cautioned not to place undue reliance on these statements. For full terms of use and disclaimers, see http://IBN.fm/Disclaimer.